INDV vs MRK
Indivior Pharmaceuticals Inc vs Merck & Co. — AI-powered side-by-side comparison
INDV
Indivior Pharmaceuticals Inc
58
Watch
VS
| Metric | INDV | MRK |
|---|
| AI Score |
58
|
70
|
| Price |
$38.42
|
$130.34
|
| P/E Ratio |
13.53×
|
103.53×
|
| ROE |
-214.3%
|
34.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
83.9%
|
75.4%
|
| Debt / Equity |
-2.45×
|
1.29×
|
| Dividend Yield |
0.0%
|
2.6%
|
| RSI (14) |
42.6
|
64.5
|
| Beta |
1.0251
|
0.207
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for INDV versus MRK.
MRK leads by 12 points.
MRK scores 70/100 (Buy) versus INDV at 58/100 (Watch).
INDV Committee View
50% agreement
6 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — high leverage (debt-to-equity 5.43) amplifies downside in a stress scenario. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- P/E of 12.8 is inexpensive for the broad market — Value
- ROE of 159.1% shows genuine earnings power backing the valuation — Value
- EPS growing 237.5% YoY — Growth
Bear Case
- Price-to-book of 49.6x prices in significant intangible value — Value
- Debt-to-equity of 5.43 adds balance-sheet risk to the value case — Value
- MACD histogram negative -- bearish momentum — Technical
MRK Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. Most analysts agree, and no major concerns are blocking a stronger rating.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- MACD histogram negative -- bearish momentum — Technical